Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience

BACKGROUND: In 2011, we reported the outcomes of pancreatic cancer (PC) patients enrolled in phase I trials at our institution from 2004 through 2009. At the time, gemcitabine and erlotinib were the only Food and Drug Administration-approved drugs for PC and median overall survival (OS) from consult...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Goldstein, Jennifer B., Tang, Chad, Hess, Kenneth R., Hong, David, Subbiah, Vivek, Janku, Filip, Fu, Siqing, Karp, Daniel D., Naing, Aung, Tsimberidou, Apostolia Maria, Wheler, Jennifer, Zinner, Ralph, Javle, Milind, Varadhachary, Gauri R., Wolff, Robert A., Fogelman, David R., Meric-Bernstam, Funda, Piha-Paul, Sarina A.
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2017
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5675623/
https://ncbi.nlm.nih.gov/pubmed/29152071
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19897
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars